Status:
RECRUITING
RT-CGM in Young Adults at Risk of DKA
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
DexCom, Inc.
Conditions:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-25 years
Phase:
NA
Brief Summary
Pilot study to evaluate the effect of real time continuous glucose monitoring (RT-CGM) on young-adults with insulin-treated diabetes, who are defined as high risk due to suboptimal HbA1c (blood glucos...
Detailed Description
Real time continous glucose monitoring (RT-CGM) is a technology that measures people's sugar level all the time, using a sensor that is placed on the skin. The sensor can be worn for 10 days and the s...
Eligibility Criteria
Inclusion
- Adolescents and young adults aged 18-25 years
- Insulin-treated diabetes \>12 months (on multiple daily injections or insulin pump therapy)
- HbA1c \> 75 mmol/mol (9%) or 1 or more DKA admissions in the last 12 months or 1 or more admissions with uncontrolled blood glucose levels in the last 12 months.
- Naïve to RT-CGM - except for short periods for use for diagnosis or monitoring purposes.
- Use of prior flash glucose monitoring is permittable
Exclusion
- Chronic kidney disease eGFR \<30ml/min
- Pregnant or planning pregnancy
- Breastfeeding
- Have active malignancy or under investigation for malignancy
- Severe visual impairment
- Reduced manual dexterity
- Unable to participate due to other factors, as assessed by the Chief Investigator
Key Trial Info
Start Date :
September 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04039763
Start Date
September 3 2020
End Date
June 30 2022
Last Update
June 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imperial College Clinical Research Facility
London, United Kingdom